AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33754659 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-piece foldable IOL
Number of subjects: 54
Study 33754659 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece IOLs
Number of subjects: 54
Study 33754826 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal coregistered photoacoustic microscopy (PAM) paired with convolutional neural network (CNN)
Number of subjects: 32
Study 33754826 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) CNN
Number of subjects: 32
Study 33755077 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial SBT
Number of subjects: 1868
Study 33755077 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed SBT
Number of subjects: 1868
Study 33755077 — intervention group
Group type: EXPERIMENTAL
Intervention: Late initial SBT (>2.3 days after intubation)
Number of subjects: 1868
Study 33755077 — intervention group
Group type: COMPARATOR
Intervention: Direct extubation
Number of subjects: 1868
Study 33755155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried serum spots (DSS) with an oral dose of 0.4 mg [13C10]retinyl acetate
Number of subjects: 72
Study 33755155 — intervention group
Group type: COMPARATOR
Intervention: Liquid plasma (LP)
Number of subjects: 72
Study 33755736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir (ATVr)
Number of subjects: 20
Study 33755792 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) plus Mycophenolate mofetil (MMF)
Number of subjects: 24
Study 33756281 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-pregnancy SDB (Apnea-Hypopnea Index ≥5)
Number of subjects: 0
Study 33756281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-pregnancy SDB
Number of subjects: 0
Study 33756281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-pregnancy nocturnal hypoxemia (% of sleep time <90% oxygen saturation)
Number of subjects: 0
Study 33756281 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing nocturnal hypoxemia from early to mid-pregnancy
Number of subjects: 0
Study 33756281 — intervention group
Group type: EXPERIMENTAL
Intervention: SDB and nocturnal hypoxemia
Number of subjects: 0
Study 33756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 0
Study 33756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 0
Study 33756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy (VMAT)
Number of subjects: 0
Study 33756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle radiotherapy
Number of subjects: 0
Study 33756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 33757307 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed therapy
Number of subjects: 4540
Study 33757307 — intervention group
Group type: COMPARATOR
Intervention: β-blocker and device therapies
Number of subjects: 4540
Study 33757459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab/ipilimumab combination therapy (Ipilimumab administered once on Day 1; Nivolumab administered on Day 1 and Day 22 for a total of two 21-day cycles).
Number of subjects: 6
Study 33757511 — intervention group
Group type: EXPERIMENTAL
Intervention: Online requesters (n=356)
Number of subjects: 3407
Study 33757511 — intervention group
Group type: COMPARATOR
Intervention: Standard requesters (n=3,051)
Number of subjects: 3407
Study 33757511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3407
Study 33757560 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 33757560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33757581 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial rotating permanent magnet stimulator (TRPMS) treatment, 10 sessions of 40 minutes each.
Number of subjects: 10
Study 33757598 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening diet quality during the pandemic
Number of subjects: 1895
Study 33757598 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during the pandemic
Number of subjects: 1895
Study 33757598 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation during the pandemic
Number of subjects: 1895
Study 33757598 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 1895
Study 33757598 — intervention group
Group type: EXPERIMENTAL
Intervention: Completing the survey in Hebrew
Number of subjects: 1895
Study 33757598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic diet quality
Number of subjects: 1895
Study 33757598 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-7 score
Number of subjects: 1895
Study 33757602 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week online mindfulness-based group intervention
Number of subjects: 0
Study 33757717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 33757788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherent patients (≥80% drug intake)
Number of subjects: 18113
Study 33757788 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent patients (<80% drug intake)
Number of subjects: 18113
Study 33757788 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥9 co-medications
Number of subjects: 18113
Study 33757788 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-event adherence rates
Number of subjects: 18113
Study 33757915 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 200
Study 33757952 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure data during pregnancy (questionnaire data, physical examination, biospecimens, medical records, objective environmental data)
Number of subjects: 9193
Study 33757952 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up every 2 years
Number of subjects: 9193
Study 33757987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CDK4/6 inhibitor palbociclib, immune checkpoint inhibitor pembrolizumab, and aromatase inhibitor letrozole (palbo+pembro+AI)
Number of subjects: 0
Study 33757987 — intervention group
Group type: COMPARATOR
Intervention: Immune checkpoint inhibitor pembrolizumab and aromatase inhibitor letrozole (pembro+AI)
Number of subjects: 0
Study 33758395 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant therapy
Number of subjects: 71
Study 33758395 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS assessment at 2 hours
Number of subjects: 71
Study 33758395 — intervention group
Group type: EXPERIMENTAL
Intervention: Early LUS assessment (first 20-30 minutes)
Number of subjects: 71
Study 33758395 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of white lung appearance for 2 hours
Number of subjects: 71
Study 33758508 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body weight and moderate coffee consumption (NW/MCC)
Number of subjects: 122
Study 33758508 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body weight and heavy coffee consumption (NW/HCC)
Number of subjects: 122
Study 33758508 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and moderate coffee consumption (OW/MCC)
Number of subjects: 122
Study 33758508 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and heavy coffee consumption (OW/HCC)
Number of subjects: 122
Study 33758521 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior vertebral body tethering (VBT)
Number of subjects: 0
Study 33758521 — intervention group
Group type: COMPARATOR
Intervention: Spinal fusion
Number of subjects: 0
Study 33758568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy Adjustment Scale (OAS)
Number of subjects: 302
Study 33758790 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 0
Study 33758790 — intervention group
Group type: EXPERIMENTAL
Intervention: %Fat
Number of subjects: 0
Study 33759264 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography measures of sleep obtained the night preceding surgery
Number of subjects: 16
Study 33759792 — intervention group
Group type: EXPERIMENTAL
Intervention: MyChoices app
Number of subjects: 11
Study 33759794 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality headset with eye-tracking device
Number of subjects: 15
Study 33760701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0
Study 33760701 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33761491 — intervention group
Group type: EXPERIMENTAL
Intervention: bulk-density sCT mimicking the current MRI-linac workflow
Number of subjects: 10
Study 33761491 — intervention group
Group type: EXPERIMENTAL
Intervention: deep learning-generated sCT
Number of subjects: 10
Study 33761491 — intervention group
Group type: EXPERIMENTAL
Intervention: bulk-density levels
Number of subjects: 10
Study 33761760 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficiency of MMP1a (Matrix Metalloprotease 1a)
Number of subjects: 0
Study 33761887 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 186
Study 33761887 — intervention group
Group type: EXPERIMENTAL
Intervention: Beliefs about medications
Number of subjects: 186
Study 33761902 — intervention group
Group type: EXPERIMENTAL
Intervention: H-HOPE intervention (Massage+ and four participatory guidance sessions)
Number of subjects: 5
Study 33761902 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of H-HOPE as standard of care
Number of subjects: 5
Study 33761902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustaining H-HOPE
Number of subjects: 5
Study 33761922 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaire for irAE detection
Number of subjects: 104
Study 33761922 — intervention group
Group type: COMPARATOR
Intervention: Clinician-reported irAE
Number of subjects: 104
Study 33761928 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole lauroxil (AL)
Number of subjects: 291
Study 33761975 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition assessment including fat-free mass (FFM), fat mass (FM), and basal metabolic rate (BMR)
Number of subjects: 363
Study 33761995 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 1430
Study 33761995 — intervention group
Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 1430
Study 33762016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training with biofeedback device (n = 18)
Number of subjects: 39
Study 33762016 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-only control group (n = 21)
Number of subjects: 39
Study 33762023 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative chronic care model (CCM) implementation facilitation after 12 months
Number of subjects: 58
Study 33762023 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative chronic care model (CCM) implementation facilitation
Number of subjects: 58
Study 33762025 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam therapeutic drug monitoring (TDM) implementation phases (not yet implemented, partially implemented, fully implemented)
Number of subjects: 30
Study 33762226 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced energy-protein (BEP) supplement and iron/folic acid (IFA) tablets
Number of subjects: 100
Study 33762226 — intervention group
Group type: COMPARATOR
Intervention: Iron/folic acid (IFA) tablets only
Number of subjects: 100
Study 33762228 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 949
Study 33762228 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 949
Study 33762230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital telemedicine system implementation
Number of subjects: 26262
Study 33762234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention including physical and laboratory assessment, individualised CV risk assessment, education, treatment recommendations, prescription adaptation, regular communication with treating physician(s), and monthly follow-up for 6 months.
Number of subjects: 99
Study 33762304 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33762322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5 PSA/MUC-1/brachyury vaccine
Number of subjects: 18
Study 33761533 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative SARS-CoV-2 vaccination
Number of subjects: 0
Study 33762734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine targeting mutant IDH1
Number of subjects: 0
Study 33763199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole Sustained Release (SR)
Number of subjects: 98
Study 33763199 — intervention group
Group type: COMPARATOR
Intervention: Pramipexole Immediate Release (IR)
Number of subjects: 98
Study 33763241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal rituximab (20 mg, IT)
Number of subjects: 10
Study 33763241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous + Intrathecal (IV+IT)
Number of subjects: 10
Study 33763241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 33763296 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) intervention for 8 weeks
Number of subjects: 0
Study 33763296 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology-motivational interviewing (PP-MI) intervention for 16 weeks
Number of subjects: 0
Study 33763296 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control conditions
Number of subjects: 0
Study 33763296 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 8-week and 16-week PP-MI interventions
Number of subjects: 0
Study 33763296 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured physical activity
Number of subjects: 0
Study 33763296 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological measures
Number of subjects: 0
Study 33763296 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related metrics (e.g. vital signs)
Number of subjects: 0
Study 33763653 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein/AS01
Number of subjects: 0
Study 33763756 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapies including post-neoadjuvant chemotherapy strategies, PARP inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and combination therapies (AKT/PI3K/mTOR-inhibitors, immunotherapeutic agents, CDK-inhibitors, antiandrogens, antiangiogenics, histone deacetylase inhibitors)
Number of subjects: 0
Study 33763818 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 104
Study 33764239 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/salm)
Number of subjects: 7787
Study 33764239 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol MART
Number of subjects: 7787
Study 33764309 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother program (text message program with 53 messages sent twice a day for the first 2 weeks and daily for weeks 3 through 6)
Number of subjects: 140
Study 33764309 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 140
Study 33764552 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle fractional radiofrequency treatment
Number of subjects: 31
Study 33764600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium levofolinate (Na-Lev) in combination with 5-fluorouracil (5-FU) administered in a single 48-hour pump
Number of subjects: 60
Study 33764600 — intervention group
Group type: COMPARATOR
Intervention: Calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) with a 2-hour infusion
Number of subjects: 60
Study 33764600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium levofolinate (Na-Lev)
Number of subjects: 60
Study 33764600 — intervention group
Group type: COMPARATOR
Intervention: Calcium levofolinate (Ca-Lev)
Number of subjects: 60
Study 33764808 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab for centrally confirmed HER2+ mGC (central HER2+/local HER2+)
Number of subjects: 548
Study 33764808 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab for local HER2+ but central HER2- mGC
Number of subjects: 548
Study 33764809 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19.28ζ-CAR T cells
Number of subjects: 50
Study 33764809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine/cyclophosphamide-based lymphodepletion
Number of subjects: 50
Study 33764809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with CD19.28ζ-CAR T cells followed by alloHSCT
Number of subjects: 50
Study 33764812 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-care adherence assessment
Number of subjects: 252
Study 33764812 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for missing medications
Number of subjects: 252
Study 33764812 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare payment method
Number of subjects: 252
Study 33764812 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of HIV acquisition
Number of subjects: 252
Study 33764812 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship status
Number of subjects: 252
Study 33764812 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of HIV status
Number of subjects: 252
Study 33764812 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition preparedness
Number of subjects: 252
Study 33764991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass, banding, vertical banded gastroplasty)
Number of subjects: 4047
Study 33764991 — intervention group
Group type: COMPARATOR
Intervention: Conventional obesity treatment (control group)
Number of subjects: 4047
Study 33764991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (surgery group)
Number of subjects: 4047
Study 33764991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047
Study 33765041 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (mean plasma level 381 μmol/L)
Number of subjects: 6602
Study 33765041 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 6602
Study 33765041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 6602
Study 33765041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 6602
Study 33765092 — intervention group
Group type: EXPERIMENTAL
Intervention: ANN model (CUHAS-ROBUST application)
Number of subjects: 487
Study 33765092 — intervention group
Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 487
Study 33765092 — intervention group
Group type: COMPARATOR
Intervention: Decision Tree
Number of subjects: 487
Study 33765092 — intervention group
Group type: COMPARATOR
Intervention: Random Forest
Number of subjects: 487
Study 33765092 — intervention group
Group type: COMPARATOR
Intervention: Extreme Gradient Boost
Number of subjects: 487
Study 33765092 — intervention group
Group type: COMPARATOR
Intervention: GeneXpert
Number of subjects: 487
Study 33765161 — intervention group
Group type: EXPERIMENTAL
Intervention: BTI-RADS (Bone Tumor Imaging Reporting and Data System)
Number of subjects: 230
Study 33765161 — intervention group
Group type: EXPERIMENTAL
Intervention: BTI-RADS
Number of subjects: 230
Study 33765164 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapies (tyrosine kinase inhibitors or mTOR inhibitor)
Number of subjects: 432
Study 33765164 — intervention group
Group type: COMPARATOR
Intervention: Control group (surveillance)
Number of subjects: 432
Study 33765164 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 432
Study 33765419 — intervention group
Group type: EXPERIMENTAL
Intervention: Iptacopan (200 mg twice daily)
Number of subjects: 10
Study 33765691 — intervention group
Group type: COMPARATOR
Intervention: Endothelin receptor antagonists (ERAs)
Number of subjects: 3322
Study 33765926 — intervention group
Group type: EXPERIMENTAL
Intervention: HCCBloodTest (Epigenomics AG)
Number of subjects: 163
Study 33765926 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS panel
Number of subjects: 163
Study 33765926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NGS panel with AFP (20 ng/mL)
Number of subjects: 163
Study 33765964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy
Number of subjects: 15000
Study 33765964 — intervention group
Group type: EXPERIMENTAL
Intervention: Core outcome and variables of interest set developed through a Delphi method
Number of subjects: 15000
Study 33766028 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-management interventions for chronic pain (specific details not provided)
Number of subjects: 12
Study 33766036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC) in patients with PAD and non-T2DM
Number of subjects: 1002
Study 33766036 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol efflux capacity (CEC) in patients with coexisting PAD and newly-diagnosed T2DM
Number of subjects: 1002
Study 33766036 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol efflux capacity (CEC) in established T2DM patients
Number of subjects: 1002
Study 33766089 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVR with INSPIRIS RESILIA aortic valve
Number of subjects: 500
Study 33766105 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical Domains Framework used to identify barriers and enablers to screening and recruitment.
Number of subjects: 15
Study 33766105 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified barriers to screening.
Number of subjects: 15
Study 33766105 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified variability in roles and procedures.
Number of subjects: 15
Study 33766146 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an internet-based foot-ankle exercise program through SOPeD, 3 times per week for 12 weeks.
Number of subjects: 14
Study 33766146 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 14
Study 33766254 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche Diagnostics hs-cTn assay
Number of subjects: 624
Study 33766254 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Diagnostics hs-cTn assay
Number of subjects: 624